bioMérieux, a global player in in vitro diagnostics, employs 15,000 people around the world, including 4,400 in France and 4,000 in the Rhône-Alpes region, where its head office and several production and research sites are located. This region, which saw the birth of the company under the leadership of the Mérieux family, remains a strategic pillar for its development.
How do bioMérieux diagnostic solutions help improve health around the world?
Our commitment to public health is the common thread in everything we do. We develop, produce and market diagnostic instruments and tests used in laboratories and hospitals to identify viruses, bacteria and other microorganisms responsible for infectious diseases.
These diagnostic tests are essential because they help healthcare professionals make the right decisions — for example, whether or not antibiotic treatment is necessary, and if so, which one — to optimize patient care. We are thus contributing to the fight against antibiotic resistance, which is responsible for 1.3 million deaths each year worldwide.
Diseases evolve very quickly and have no borders: how can your teams anticipate tomorrow’s epidemics?
bioMérieux stands out for its long-term vision, which translates into a sustained innovation policy. Each year, we reinvest approximately 12% of our turnover in research and development, which is well above the average for our sector. The objective is to offer diagnostic tests that always better meet the needs of healthcare professionals and the patients they treat.
Given the challenge posed by the fight against antibiotic resistance, we have therefore chosen to allocate 75% of our R&D effort to it. At bioMérieux, innovation is a state of mind that we cultivate within our teams, with work environments conducive to creativity and development.
bioMérieux has 6 sites in Rhône-Alpes: what does this regional presence mean to you?
bioMérieux is very attached to its French and Rhône-Alpine roots, which is where it all began under the leadership of the Mérieux family. In addition to our head office, we have several production units, cutting-edge R&D sites and an international distribution center in the Rhône-Alpes region.
We continually invest in our sites to support our growth while ensuring we reduce our carbon footprint and strengthen the quality of life at work for our employees. Today, more than 90% of bioMérieux’s activity is carried out internationally with a third of our workforce in France.
NAMELY
With 9 sites in France, including 6 in Rhône-Alpes, bioMérieux devotes 12% of its turnover to research and development, thus affirming its commitment to innovation to respond to public health challenges.
